Beatrice Detti1, Rolando M D'Angelillo2, Gianluca Ingrosso3, Emanuela Olmetto4, Giulio Francolini1, Luca Triggiani5, Alessio Bruni6, Simona Borghesi7, Simona Fondelli8, Tommaso Carfagno9, Roberto Santini10, Riccardo Santoni3, Luca E Trodella2, Lorenzo Livi1. 1. Department of Radiation Oncology, AOU Careggi, Florence, Italy. 2. Department of Radiation Oncology, University Campus Bio-Medico di Roma, Rome, Italy. 3. Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, Tor Vergata General Hospital, Rome, Italy. 4. Department of Radiation Oncology, AOU Careggi, Florence, Italy e.olmetto@gmail.com. 5. Department of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy. 6. Department of Radiation Oncology, AOU Policlinico di Modena, Modena, Italy. 7. Department of Radiation Oncology, Ospedale San Donato Arezzo, Arezzo, Italy. 8. Department of Radiation Oncology, Azienda USL Toscana-Centro, Ospedale S. Maria Annunziata, Florence, Italy. 9. Department of Radiation Oncology, Azienda Ospedaliera Universitaria Senese, Siena, Italy. 10. Department of Radiation Oncology, Ospedale San Jacopo Pistoia, Pistoia, Italy.
Abstract
BACKGROUND/AIM: This multicenter, retrospective, 'field-practice' study investigated treatment outcomes of ongoing abiraterone therapy with the addition of radiotherapy (RT) - initiated for oligoprogression or with a palliative intent. PATIENTS AND METHODS: Consecutive patients affected by metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate were considered if they had received RT after the initiation of abiraterone treatment. RESULTS: A total of 32 patients were enrolled in the study. Median duration of abiraterone treatment was 13.0 months (range=3.8-40.9 months). Median duration of abiraterone treatment before RT was 5.9 months (range=0.4-40.0 months), and 7.2 months after RT (range=0.1-29.7 months). Median progression-free survival (PFS) was 12.6 months (95%CI=10.5-14.7) from the initiation of abiraterone treatment. From RT administration, PFS was 9.6 months (95%CI=6.4-12.9). Median overall survival (OS) since abiraterone initiation was 18.9 months (95%CI=4.7-33.0). CONCLUSION: RT prolongs abiraterone treatment in mCRPC patients leading to better clinical outcomes with this molecule. Copyright
BACKGROUND/AIM: This multicenter, retrospective, 'field-practice' study investigated treatment outcomes of ongoing abiraterone therapy with the addition of radiotherapy (RT) - initiated for oligoprogression or with a palliative intent. PATIENTS AND METHODS: Consecutive patients affected by metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate were considered if they had received RT after the initiation of abiraterone treatment. RESULTS: A total of 32 patients were enrolled in the study. Median duration of abiraterone treatment was 13.0 months (range=3.8-40.9 months). Median duration of abiraterone treatment before RT was 5.9 months (range=0.4-40.0 months), and 7.2 months after RT (range=0.1-29.7 months). Median progression-free survival (PFS) was 12.6 months (95%CI=10.5-14.7) from the initiation of abiraterone treatment. From RT administration, PFS was 9.6 months (95%CI=6.4-12.9). Median overall survival (OS) since abiraterone initiation was 18.9 months (95%CI=4.7-33.0). CONCLUSION: RT prolongs abiraterone treatment in mCRPC patients leading to better clinical outcomes with this molecule. Copyright
Authors: Ciro Franzese; Matteo Perrino; Marco Antonio Marzo; Marco Badalamenti; Davide Baldaccini; Giuseppe D'Agostino; Beatrice Marini; Fabio De Vincenzo; Paolo Andrea Zucali; Marta Scorsetti Journal: Clin Exp Metastasis Date: 2022-02-21 Impact factor: 5.150
Authors: Christoph Henkenberens; Thorsten Derlin; Frank Bengel; Tobias L Ross; Markus A Kuczyk; Frank A Giordano; Gustavo R Sarria; Leonard Christopher Schmeel; Hans Christiansen; Christoph A J von Klot Journal: Front Oncol Date: 2021-04-19 Impact factor: 6.244
Authors: Maria Massaro; Giuseppe Facondo; Gianluca Vullo; Anna Maria Aschelter; Alessandro Rossi; Vitaliana De Sanctis; Paolo Marchetti; Mattia Falchetto Osti; Maurizio Valeriani Journal: Front Oncol Date: 2021-09-23 Impact factor: 6.244